
Supplement 1: The progressive gating scheme to enumerate antigen specific T cells. A. Gating strategy to identify, in succession, single cells, live lymphocytes, T-cells, and CD4 or CD8 T-cell lineages. B. Illustration of PBMC from a representative vaccinated participant following RT peptide stimulation or mock stimulation (bkg) at week 6 after vaccination. The fraction of CD40-L, TNF-a, IL-2, or IFN-r expressing cells was defined based on individual gates; Boolean gate combinations were used to enumerate combinations of expression of cytokines.

<u>Footnote</u>: IL-2 interleukin-2; TNF- α = tumor necrosis factor- α ; IFN- γ = interferon- γ ; CD40L = CD40-ligand



Supplement 2. $CD4^+$ T-cells count using crude values and HIV-1 viral load using log_{10} -transformed values at screening (modified total vaccinated cohort) <u>Footnote</u>: $F4/AS01_B$ = participants randomized to receive three doses of $F4/AS01_B$ at Weeks 0, 4 and 28 or two doses of $F4/AS01_B$ at Weeks 0 and 4, and one dose of placebo at Week 28; Control = participants randomized to receive three doses of placebo at Weeks 0, 4 and 28 ; N = total number of participants; SD = Standard deviation.

Characteristic		F4/AS01 _B (N=125)	Control (N=60)
CD4 ⁺ T-cells count at screening	Median (Range)	646 (502, 1801)	669.5 (501, 1067)
Viral load at screening (log ₁₀ copies/mL)	Mean (SD)	4.13 (0.42)	4.11 (0.40)

Supplement 3. Serious adverse events reported during the entire study period (total vaccinated cohort)

<u>Footnote:</u> $F4/AS01_B_3$ = participants randomized to receive three doses of $F4/AS01_B$ at Weeks 0, 4 and 28; $F4/AS01_B_2$ = participants randomized to receive two doses of $F4/AS01_B$ at Weeks 0 and 4, and one dose of placebo at Week 28;

Control = participants randomized to receive three doses of placebo at Weeks 0, 4 and 28. * recovering at time of study end.

Group	Serious adverse event	Dose	Day of onset	Causality	Outcome
F4/AS01 _{B_3}	Gastroenteritis due to shigella	1	1	No	Recovered
	Appendicitis	3	56	No	Recovered
F4/AS01 _B _2	Lymph node tuberculosis	2	95	No Recover	
	Anxiety	2	128	No	Recovered
F4/AS01 _B _2	Angioedema	2	0	Yes	Recovered
F4/AS01 _B _2	Hepatitis C	3	0	No	Recovering
Control	Skull fracture	1	32	No	Recovered
Control	Pre-eclampsia	2	238	No	Recovered
	Anemia	2	170	No	Recovered
	Hemorrhage intracranial	2	241	No	Recovered
	Hydrocephalus	2	241	No	Recovered
	Hydronephrosis	2	241	No	Recovered

Supplement 4. Ophthalmologic results at baseline and at study conclusion (total vaccinated cohort)

<u>Footnote:</u> $F4/AS01_B_3$ = participants randomized to receive three doses of $F4/AS01_B$ at Weeks 0, 4 and 28; $F4/AS01_B_2$ = participants randomized to receive two doses of $F4/AS01_B$ at Weeks 0 and 4, and one dose of placebo at Week 28;

Control = participants randomized to receive three doses of placebo at Weeks 0, 4 and 28; N = total number of participants in the group; n (%) = number (percentage) of participants in a given category; Normal = category < 1.0 for both eyes and all 3 eye exams (slit lamp cortical, slit lamp nuclear and slit lamp subcapsular);


Abnormal category 1.0 for at least one eye and one exam among slit lamp cortical, slit lamp nuclear and slit lamp subcapsular.

		$F4/AS01_B_3$ $N = 62$	$F4/AS01_{B}_{2}$ $N = 64$	Control N = 64
Category at baseline	Categories at study end	n (%)	n (%)	n (%)
Abnormal	Abnormal	2 (66.7)	1 (20.0)	2 (50.0)
	Normal	1 (33.3)	4 (80.0)	2 (50.0)
	Unknown	0 (0.0)	0 (0.0)	0 (0.0)
	Missing	1 (-)	0 (-)	0 (-)
Normal	Abnormal	1 (2.0)	2 (4.0)	0 (0.0)
	Normal	50 (98.0)	47 (94.0)	48 (98.0)
	Unknown	0 (0.0)	1 (2.0)	1 (2.0)
	Missing	6 (-)	8 (-)	10 (-)
Unknown	Abnormal	0 (0.0)	0 (0.0)	0 (0.0)
	Normal	0 (0.0)	0 (0.0)	0 (0.0)
	Unknown	1 (100)	1 (100)	1 (100)

Supplement 5. Change in HIV-1 viral load from baseline to Week 48 (ratio of each crude value over baseline crude value) in ART-naive HIV-infected participants (modified total vaccinated cohort).

<u>Footnote:</u> $F4/AS01_B_3$ = participants randomized to receive three doses of $F4/AS01_B$ at Weeks 0, 4 and 28; $F4/AS01_B_2$ = participants randomized to receive two doses of $F4/AS01_B$ at Weeks 0 and 4, and one dose of placebo at Week 28;


Control participants randomized to receive three doses of placebo at Weeks 0, 4 and 28. The boxplot: the central box shows the interquartile range (Q1–Q3), with the thick horizontal line representing the median (Q2), the whiskers (above and below the box), the maximum and the minimum, and the circles, the observed individual data.



Supplement 6. Kinetics of the geometric mean of changes in HIV-1 viral load from baseline (modified total vaccinated cohort)

<u>Footnote:</u> $F4/AS01_B_3$ = participants randomized to receive three doses of $F4/AS01_B$ at Weeks 0, 4 and 28; $F4/AS01_B_2$ = participants randomized to receive two doses of $F4/AS01_B$ at Weeks 0 and 4, and one dose of placebo at Week 28;


Control = participants randomized to receive three doses of placebo at Weeks 0, 4 and 28. Errors bars represent 95% confidence intervals.




Supplement 7. Kinetics of the mean of changes in CD4⁺ T-cells count from baseline (modified total vaccinated cohort)

<u>Footnote:</u> $F4/AS01_B_3$ = participants randomized to receive three doses of $F4/AS01_B$ at Weeks 0, 4 and 28; $F4/AS01_B_2$ = participants randomized to receive two doses of $F4/AS01_B$ at Weeks 0 and 4, and one dose of placebo at Week 28;

Control = participants randomized to receive three doses of placebo at Weeks 0, 4 and 28. Errors bars represent 95% confidence intervals.




Supplement 8. Reverse cumulative curves Kaplan-Meyer graphical presentation of time to ART initiation after the first vaccination (modified total vaccinated cohort) <u>Footnote:</u> $F4/AS01_B_3$ = participants randomized to receive three doses of $F4/AS01_B$ at Weeks 0, 4 and 28; $F4/AS01_B_2$ = participants randomized to receive two doses of $F4/AS01_B$ at Weeks 0 and 4, and one dose of placebo at Week 28; Placebo = participants randomized in Control group to receive three doses of placebo at Weeks 0, 4 and 28. ART = anti-retroviral therapy



Supplement 9. Reverse cumulative curves Kaplan-Meyer graphical presentation of occurrence of any HIV-related clinical event after the first vaccination (modified total vaccinated cohort)

<u>Footnote:</u> $F4/AS01_B_3$ = participants randomized to receive three doses of $F4/AS01_B$ at Weeks 0, 4 and 28; $F4/AS01_B_2$ = participants randomized to receive two doses of $F4/AS01_B$ at Weeks 0 and 4, and one dose of placebo at Week 28;

Placebo = participants randomized in control group to receive three doses of placebo at Weeks 0, 4 and 28. HIV related clinical events are (a) confirmed CD4⁺ T-cell count < 350 cells/mm (b) confirmed HIV viral load > 100 000 copies/mL (c) clinical disease progression.



Supplement 10. Percentage of responders in terms of F4-specific CD40L⁺CD4⁺ T-cell vaccine expressing at least IL-2 (alone or together with other cytokines) <u>Footnote:</u> F4/AS01_B_3 = participants randomized to receive three doses of F4/AS01_B at Weeks 0, 4 and 28; F4/AS01_B_2 = participants randomized to receive two doses of F4/AS01_B at Weeks 0 and 4, and one dose of placebo at Week 28. Participants with undetectable cytokine secretion at pre-vaccination were defined as responders if they had 0.08% of CD40L + CD4 + T-cells expressing at least one cytokine. In participants with detectable cytokine secretion at pre-vaccination, response was defined as a > 2-fold increase from baseline in CD40L⁺CD4⁺ T-cells expressing at least IL-2 (interleukin-2).

Time point	F4/AS01 _B _3	F4/AS01 _B _2	Placebo
Week 6	78	75	-
Week 28	39	33	-
Week 30	76	37	-
Week 48	51	22	-
Pooled post-vaccination timepoints	-	-	30


Supplement 11. Between group comparison for the number of each antigen-specific CD40L⁺CD4⁺ T-cell expressing at least IL-2 (alone or together with other cytokines): geometric mean ratio per million CD4⁺ T-cells (according-to-protocol cohort for immunogenicity)

<u>Footnote:</u> $F4/AS01_B_3$ = participants randomized to receive three doses of $F4/AS01_B$ at Weeks 0, 4 and 28; $F4/AS01_B_2$ = participants randomized to receive two doses of $F4/AS01_B$ at Weeks 0 and 4, and one dose of placebo at Week 28;

Control = participants randomized to receive three doses of placebo at Weeks 0, 4 and 28; GMT = geometric mean titer; 95% CI = 95% confidence intervals.


Timepoint	antigen	F4/AS01 _B group	GMT ratio (F4/AS01 _B over Control group) Value (95% CI)
	Nef	pooled F4/AS01 $_{B}_3$ and F4/AS01 $_{B}_2$	1.44 (0.85, 2.46)
Week 0	p17	pooled F4/AS01 $_{\rm B}_3$ and F4/AS01 $_{\rm B}_2$	0.86 (0.53, 1.39)
	p24	pooled F4/AS01 $_{\rm B}_3$ and F4/AS01 $_{\rm B}_2$	0.94 (0.63, 1.42)
	RT	pooled F4/AS01 $_{\rm B}_3$ and F4/AS01 $_{\rm B}_2$	1.66 (1.09, 2.55)
	Nef	pooled F4/AS01 $_{\rm B}_3$ and F4/AS01 $_{\rm B}_2$	9.15 (5.13, 16.30)
Week 6	p17	pooled F4/AS01 $_{B}_3$ and F4/AS01 $_{B}_2$	2.43 (1.53, 3.85)
	p24	pooled F4/AS01 $_{B}_3$ and F4/AS01 $_{B}_2$	1.71 (1.03, 2.83)
	RT	pooled F4/AS01 $_{\rm B}_3$ and F4/AS01 $_{\rm B}_2$	6.57 (3.98, 10.84)
	Nef	F4/AS01 _B _3	23.46 (12.39, 44.44)
Week 30	p17	F4/AS01 _B _3	2.40 (1.40, 4.11)
	p24	F4/AS01 _B _3	2.41 (1.39, 4.16)
	RT	F4/AS01 _B _3	6.33 (3.18, 12.60)
Week 48	Nef	F4/AS01 _B _3	8.58 (3.98, 18.50)
	p17	F4/AS01 _B _3	2.25 (1.19, 4.25)
	p24	F4/AS01 _B _3	1.81 (1.00, 3.72)
	RT	F4/AS01 _B _3	4.21 (2.11, 8.40)

Supplement 12. (A) Percentage of F4-specific CD8⁺ T-cells expressing at least one cytokine, (B) Cytokine co-expression profile of F4-specific CD8⁺ T-cells in the F4/AS01_B 3 group and the Control group at Week 30 and (C) pie charts of the cytokine co-expression of F4-specific CD8⁺ T-cells at each timepoint in the three groups (according-to-protocol cohort for immunogenicity) <u>Footnote:</u> $F4/AS01_B$ 3 = participants randomized to receive three doses of $F4/AS01_B$ at Weeks 0, 4 and 28; F4/AS01_B 2° = participants randomized to receive two doses of F4/AS01_B at Weeks 0 and 4, and one dose of placebo at Week 28; Control = participants randomized to receive three doses of placebo at Weeks 0, 4 and 28; IL-2 interleukin-2; TNF- α tumor necrosis factor- α ; IFN- γ interferon- γ ; CD40L CD40-ligand. The boxplot: the central box shows the interquartile range (Q1-Q3), with the thick horizontal line representing the median (Q2), and the whiskers (above and below the box), the maximum and the minimum. The percentage of $CD8^+$ T-cells expressing cytokines in response to the fusion protein F4 was determined by adding the individual frequencies of the CD8⁺ T-cell response to each of the four individual antigens. Whiskers were not added to Supplement 10B for clarity. The sizes of the pie charts represent the proportions of total CD8⁺ T-cells producing at least one cytokine.



Supplement 13. Antibody geometric mean concentrations (GMCs) against p17 (A), p24 (B), RT (C) and Nef (D) at each timepoint (ATP cohort for immunogenicity) <u>Footnote</u>: $F4/AS01_B_3$ = participants randomized to receive three doses of $F4/AS01_B$ at Weeks 0, 4 and 28; $F4/AS01_B_2$ = participants randomized to receive two doses of $F4/AS01_B$ at Weeks 0 and 4, and one dose of placebo at Week 28; Control = participants randomized to receive three doses of Pacebo at Weeks 0, 4 and

28. Errors bars represent 95% confidence intervals. ATP According-to-Protocol. EU ELISA Units



Supplement 14. Relationship between cell mediated immunogenicity (% $CD40L^+ CD4^+$ T-cells expressing at least IL-2) and change from baseline in (A) VL or (B) CD4 count at Week 48 (ATP cohort for immunogenicity)

<u>Footnote</u>: $F4/AS01_B_3$ = participants randomized to receive three doses of $F4/AS01_B$ at Weeks 0, 4 and 28; $F4/AS01_B_2$ = participants randomized to receive two doses of $F4/AS01_B$ at Weeks 0 and 4, and one dose of placebo at Week 28;

Control = participants randomized to receive three doses of placebo at Weeks 0, 4 and 28. ATP = According-to-Protocol.

